DiscoverIPO

Attovia Therapeutics, Inc.

expected
Aug 4, 2026
status
Expected
proposed ticker
ATTO
Industry
Biological Products, (No Diagnostic Substances)
Headquarters
United States
Incorporated in
DE
Exchange
NASDAQ
Price range
$15.00 – $17.00
Shares offered
12.5M shares
Offer size
$230M
Underwriters
MS, LEER, CITI, RBC, LFSCI

Overview

Business overview

Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biotherapeutics for immune-mediated diseases. The company employs its ATTOBODY biologics platform to create innovative treatments targeting established pathways. Their lead product, ATTO-1310, is in clinical trials for chronic pruritus and high-itch atopic dermatitis, with other candidates, ATTO-2306 and ATTO-1091, also in development for related immune-mediated conditions.

Revenue model

Not disclosed in the provided filing text.

Competitive strengths

  • Innovative ATTOBODY biologics platform
  • Focus on high unmet need in immune-mediated diseases
  • Pipeline diversity with multiple product candidates
  • Strong initial clinical data supporting ATTO-1310's efficacy

Risk factors

  • High degree of risk associated with investing in common stock
  • Dependence on clinical trial outcomes
  • Potential challenges in securing funding for continued development
  • Market competition from established therapies

Use of proceeds

Not disclosed in the provided filing text.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

Attovia Therapeutics, Inc.'s offering is currently expected on NASDAQ. The expected date is Aug 4, 2026. Shares are expected to be offered at $15.00 – $17.00, with 12.5M shares on offer, for a total offer size of $230M. The proposed ticker is ATTO. Underwriters on the deal include MS, LEER, CITI, RBC, LFSCI. Attovia Therapeutics, Inc. is headquartered in United States and incorporated in DE. It is classified under Biological Products, (No Diagnostic Substances).

Attovia Therapeutics, Inc. has filed 5 times, starting with a S1/A on Jul 29, 2026.

Frequently asked questions

When is Attovia Therapeutics, Inc. expected to go public?

Attovia Therapeutics, Inc. is expected to list on Aug 4, 2026.

What exchange will Attovia Therapeutics, Inc. list on?

Attovia Therapeutics, Inc. is listing on NASDAQ.

How much is Attovia Therapeutics, Inc. raising in its IPO?

Attovia Therapeutics, Inc.'s offering is expected to raise $230M.

What is Attovia Therapeutics, Inc.'s ticker symbol?

Attovia Therapeutics, Inc.'s proposed ticker is ATTO.

Where this data comes from

New York Stock Exchange listings data. Retrieved Aug 1, 2026.

View the original filing on NYSE →

All filings for this company

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.

We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy